Adrienn Baán

Adrienn Baán

Auto-generated profile, based on publicly available information

Adrienn Baán

Laboratory of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CJCedric Joossen
Cedric Joossen
ABAdrienn Baán
Adrienn Baán
CMCarlos Moreno-Cinos
Carlos Moreno-Cinos
JJJurgen Joossens
Jurgen Joossens
NCNathalie Cools
Nathalie Cools
PCPaul Cos
Paul Cos
Dry eye syndrome (DES), a multifactorial disorder which leads to ocular discomfort, visual disturbance and tear film instability, has a rising prevalence and limited treatment options. In this study, a newly developed trypsin-like serine protease inhibitor (UAMC-00050) in a tear drop formulation was evaluated to treat ocular inflammation. A surgical animal model of dry eye was employed to investigate the potential of UAMC-00050 on dry eye pathology. Animals treated with UAMC-00050 displayed a significant reduction in ocular surface damage after evaluation with sodium fluorescein, compared to untreated, vehicle treated and cyclosporine-treated animals. The concentrations of IL-1α and TNF-α were also significantly reduced in tear fluid from UAMC-00050-treated rats. Additionally, inflammatory cell infiltration in the palpebral conjunctiva (CD3 and CD45), was substantially reduced. An accumulation of pro-MMP-9 and a decrease in active MMP-9 were found in tear fluid from animals treated with UAMC-00050, suggesting that trypsin-like serine proteases play a role in activating MMP-9 in ocular inflammation in this animal model. Comparative qRT-PCR analyses on ocular tissue indicated the upregulation of tryptase, urokinase plasminogen activator receptor (uPAR) and protease-activated receptor 2 (PAR2). The developed UAMC-00050 formulation was stable up to 6 months at room temperature in the absence of light, non-irritating and sterile with compatible pH and osmolarity. These results provide a proof-of-concept for the in vivo modifying potential of UAMC-00050 on dry eye pathology and suggest a central role of trypsin-like serine proteases and PAR2 in dry eye derived ocular inflammation.

1 August 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ABAdrienn Baán
Adrienn Baán
PAPeter Adriaensens
Peter Adriaensens
JLJoris Lammens
Joris Lammens
RHRené Delgado Hernandez
René Delgado Hernandez
WBWim Vanden Berghe
Wim Vanden Berghe
FKFilip Kiekens
Filip Kiekens

1 May 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ISIrene G. Salado
Irene G. Salado
ABAdrienn Baán
Adrienn Baán
TVTomas Verdeyen
Tomas Verdeyen
AMAn Matheeussen
An Matheeussen
GCGuy Caljon
Guy Caljon
KAKoen Augustyns
Koen Augustyns